FDA OKs Hibsago as first antisense for chronic hepatitis B
The FDA approved bepirovirsen as the first antisense oligonucleotide for chronic hepatitis B virus infection, alongside existing antiviral therapy for eligible adults without cirrhosis. Bepirovirsen (Hibsago, GSK) is indicated for adults who have taken HBV antiviral therapy for at least 6 months, have suppressed levels
